Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Ali Afshar OmeriehNils DebusMonika UhrigThomas A HopeMichael J EvansTim Holland-LetzFrederik L GieselKlaus KopkaBoris HadaschikClemens KratochwilUwe Haberkorn

Published in: European journal of nuclear medicine and molecular imaging (2018)

Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT.

Keyphrases

pet ct
prostate cancer
positron emission tomography
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
radical prostatectomy
computed tomography